Phase 1/2a Study Of Double Immune Suppression Blockade By Combining A Csf1r Inhibitor (Pexidartinib/Plx3397) With An Anti Pd-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors.
Annals of Oncology（2016）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined